QUOTE AND NEWS
FiercePharma  Apr 8  Comment 
Novo Nordisk says the FDA has accepted its reapplication of its long-acting insulin Tresiba, setting it up for an October decision and a launch yet this year if approved this time around. Execs at Sanofi will certainly be watching the calendar...
SeekingAlpha  Apr 4  Comment 
GenEng News  Apr 2  Comment 
Schrödinger said today it will provide computational resources to Sanofi for up to 10 drug discovery programs, under a $120 million, multi-year collaboration launched by the companies. The provider of enterprise software solutions and...
FiercePharma  Mar 30  Comment 
Sanofi Chairman Serge Weinberg says his company can do without dealmaking. And good thing, Weinberg told Les Echos--because the potential buys on the market are too expensive.
FiercePharma  Mar 27  Comment 
Novo Nordisk will soon resubmit Tresiba to the FDA, earlier than once expected. The escalated timeline provided a substantial boost to Novo's shares, but the news adds pressure to Sanofi's new CEO since Tresiba targets Lantus, the French...
Motley Fool  Mar 25  Comment 
GlaxoSmithKline's share price has stagnated under CEO Andrew Witty. Is it time for a change?
FierceBiotech  Mar 24  Comment 
Thomson Reuters is predicting a big year for blockbuster drugs. Its analysts forecast 11 drugs approved this year will go on to rack up blockbuster sales in 2019, with new treatments from Bristol-Myers Squibb, Sanofi and Novartis leading the pack.
GenEng News  Mar 20  Comment 
Evotec said yesterday it hammered out a definitive agreement for a five-year, minimum-guaranteed €250 million (nearly $270 million) strategic alliance with Sanofi focused on developing multiple products. The announcement confirms a deal the...




 

Very nice site!

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki